About Q Biomed (OTCMKTS:QBIO)
Q BioMed, Inc., formerly ISMO Tech Solutions, Inc., is a biomedical acceleration and development company. The Company is focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. The Company intends to acquire multiple assets over time and across a spectrum of healthcare related products, companies and sectors. The Company intends to develop these assets to provide returns through organic growth, out-licensing, sale or spin-off into new public companies. The Company holds license for a generic drug, Strontium Chloride (SR89). SR89 is a radiopharmaceutical agent and indicated for the treatment of pain associated with metastatic bone cancer. Its asset, MAN-01, is indicated for the treatment of glaucoma. MAN-01 is in pre-clinical stage. The Company is assessing multiple biomedical assets in various areas of healthcare and drug development. It is pursuing a pipeline of therapeutics, diagnostics and orphan drug candidates.
Industry, Sector and Symbol
SymbolOTCMKTS:QBIOPrevious Symbol: NASDAQ:QBIO
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value($0.22) per share
Price / Book-20.00
Return on EquityN/A
Return on Assets-893.92%
Frequently Asked Questions for Q Biomed (OTCMKTS:QBIO)
What is Q Biomed's stock symbol?
Q Biomed trades on the OTCMKTS under the ticker symbol "QBIO."
When will Q Biomed make its next earnings announcement?
Who are some of Q Biomed's key competitors?
Some companies that are related to Q Biomed include Vermillion (VRML), Aralez Pharmaceuticals (ARLZ), Gemphire Therapeutics (GEMP), Evogene (EVGN), ProQR Therapeutics N.V. (PRQR), Nuvectra Corporation (NVTR), CytoDyn (CYDY), Galectin Therapeutics (GALT), Novan (NOVN), Five Star Quality Care (FVE), Novelion Therapeutics (NVLN), BioLife Solutions (BLFS), Arch Therapeutics (ARTH), MEI Pharma (MEIP), Lipocine (LPCN), ADMA Biologics (ADMA), Aevi Genomic Medicine (GNMX) and ContraFect Corporation (CFRX).
How do I buy Q Biomed stock?
Shares of Q Biomed can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Q Biomed's stock price today?
One share of Q Biomed stock can currently be purchased for approximately $4.40.
How big of a company is Q Biomed?
Q Biomed has a market capitalization of $49.82 million.
How can I contact Q Biomed?
Q Biomed's mailing address is 501 MADISON AVENUE 14TH FLOOR, NEW YORK NY, 10022. The company can be reached via phone at 212-588-0022.
MarketBeat Community Rating for Q Biomed (QBIO)MarketBeat's community ratings are surveys of what our community members think about Q Biomed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Q Biomed (OTCMKTS:QBIO) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Q Biomed (OTCMKTS:QBIO)
Analysts' Ratings History for Q Biomed (OTCMKTS:QBIO)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Q Biomed (OTCMKTS:QBIO)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Q Biomed (OTCMKTS:QBIO)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Q Biomed (OTCMKTS:QBIO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Q Biomed (OTCMKTS QBIO)
Institutional Ownership Percentage: 0.01%
Insider Trades by Quarter for Q Biomed (OTCMKTS QBIO)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/28/2017||William S Rosenstadt||General Counsel||Sell||55,051||$4.10||$225,709.10|| |
Latest Headlines for Q Biomed (OTCMKTS QBIO)
Q Biomed (OTCMKTS QBIO) Chart for Thursday, November, 23, 2017